Saturday 17 October 2026
Export RVTY’s income statement to Excel — free account
Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
152.64
2.07
−1.34%
Follow RVTY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
52.98 | 41.92 | 46.51 | 44.05 |
+8 more quarters Free account |
P/S ratio |
4.26 | 3.38 | 3.95 | 3.60 | |
P/FCF ratio |
21.97 | 19.73 | 22.35 | 20.54 | |
P/Operating CF |
64.68 | 85.04 | 61.97 | 73.04 | |
P/B ratio |
1.72 | 1.36 | 1.56 | 1.37 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.01 | 4.19 | 4.75 | 4.41 | |
EV/EBITDA |
18.82 | 15.62 | 17.71 | 15.99 | |
EV/Operating CF |
23.26 | 21.31 | 23.29 | 21.56 | |
EV/FCF |
25.83 | 24.46 | 26.91 | 25.18 | |
Quick Ratio |
1.36 | 1.25 | 1.25 | 1.32 | |
Current Ratio |
1.80 | 1.72 | 1.68 | 1.75 | |
Net Debt/EBITDA |
11.33 | 12.89 | 10.66 | 12.33 | |
Debt/Assets |
26.61% | 26.74% | 26.46% | 26.48% | |
Debt/Equity |
0.44 | 0.45 | 0.44 | 0.44 | |
Asset Turnover |
0.24 | 0.24 | 0.23 | 0.23 | |
Operating CF/Net income |
3.70 | 2.83 | 1.85 | 2.97 | |
Capex/Depreciation |
(0.08) | (0.10) | (0.19) | (0.18) | |
Interest Coverage |
3.46 | 2.93 | 5.54 | 3.12 | |
Research and Development Expense of Revenue |
6.71% | 8.14% | 7.54% | 7.27% | |
Selling, General and Administrative Expense of Revenue |
38.18% | 35.70% | 32.61% | 34.61% | |
Intangible Assets out of Total Assets |
0.73 | 0.74 | 0.74 | 0.74 | |
Share Based Compensation of Revenue |
1.47% | 1.23% | (0.53%) | 1.30% | |
Graham Net Nets |
(0.20) | (0.27) | (0.24) | (0.26) | |
Graham Number |
55.33 | 54.95 | 53.96 | 53.49 | |
Earnings Yield |
1.89% | 2.39% | 2.15% | 2.27% | |
Free Cash Flow Yield |
4.55% | 5.07% | 4.47% | 4.87% | |
Revenue per Share |
6.54 | 6.36 | 6.62 | 6.06 | |
Operating CF per Share |
1.72 | 1.03 | 1.56 | 1.20 | |
Capex per Share |
(0.07) | (0.10) | (0.17) | (0.16) | |
Free Cash Flow per Share |
1.65 | 0.93 | 1.39 | 1.04 | |
Cash per Share |
9.17 | 7.69 | 7.89 | 8.07 | |
Shareholders Equity per Share |
64.78 | 64.22 | 62.21 | 63.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
64.78 | 64.22 | 62.21 | 63.91 | |
Free Cash Flow |
183.91 | 104.46 | 161.79 | 120.00 | |
Working Capital |
1,021.36 | 889.67 | 908.50 | 921.05 | |
Capital Expenditures |
(8.04) | (10.77) | (20.17) | (18.50) | |
Net Current Asset Value |
(2,519.35) | (2,685.53) | (2,678.30) | (2,619.27) | |
EV/EBIT |
40.68 | 33.71 | 38.07 | 34.10 | |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.03 | |
Price to Operating Income |
34.60 | 27.20 | 31.62 | 27.82 | |
| Other line items | |||||
Average Receivables |
685.16 | 654.40 | 688.54 | 641.20 | |
Average Payables |
171.95 | 173.88 | 176.46 | 176.10 | |
Average Inventory |
383.48 | 384.41 | 373.54 | 392.24 | |
Average Assets |
12,204.31 | 12,178.66 | 12,280.45 | 12,454.35 | |
Average Common Equity |
7,392.46 | 7,409.93 | 7,458.62 | 7,648.80 |
Columns are period end dates